Scientists hail the first effective treatment for skin cancer victims

'Personalised' drug keeps melanoma at bay for six months, trials demonstrate

Scientists have developed the first "personalised" drug shown to be effective against advanced melanoma, the deadliest type of skin cancer which is on the rise in Britain.

Warnings about the risks of melanoma were heightened this weekend as the fine weather drew thousands to sunbathe outdoors, putting them at increased risk. "Binge tanning", where sunbathers allow their skin to burn in their eagerness to get a tan, is a key cause of the cancer.

Melanoma, which starts as a blemish or change to a mole on the skin, is treatable in its early stages but once it has spread to other organs such as the lungs and liver there are no treatment options. Patients with melanoma that has spread usually die within months.

In the first trial in human beings of the new drug, known only by its code name PLX4032, those treated lived on average for six months without their disease getting worse. Asked what difference the drug made, one doctor said that for the first time he had "time to get to know my patients".

The drug is the first of half a dozen agents which are in development, designed to target advanced melanomas that are "BRAF positive", meaning they have a specific genetic make-up containing the BRAF mutation.

They are the harbingers of a revolution in cancer medicine which is seeing the development of an increasing number of drugs tailored to the genetic make-up of individual cancers, so treatment can be personalised for each patient, not just determined by the cancer's location or stage.

BRAF is a cancer-causing mutation which is implicated in 60 per cent of melanomas and 8 per cent of other solid cancers. The new drug works by selectively targeting and destroying tumour cells that carry the BRAF gene but it has no effect against melanomas that lack the mutation. It is also being developed for use in other cancers including bowel cancer.

In the Phase 1 trial, half of the 16 patients treated saw their tumours shrink by 30 per cent and survival without disease progression was extended. The results were presented at the American Society for Clinical Oncology meeting in Orlando yesterday.

Keith Flaherty, an assistant professor at the Abramson Cancer Centre of the University of Pennsylvania, who led the trial, said: "Seven years after BRAF mutations were first identified, we have validation that this mutation is a cancer driver and therapeutic target. In addition to a new and important chapter in the story of targeted therapy development in cancer, we are especially excited for our melanoma patients for whom there are few treatment options."

In the UK, the number of people diagnosed with melanoma has risen fourfold since the 1970s and has exceeded 10,000 annually for the first time. The typical victim is the pale-skinned office worker who spends two weeks broiling on a Mediterranean beach until their skin is red and blistered. Covering up in the midday sun and using high-factor sun cream is the best defence against the cancer.

Roche, the Swiss multinational pharmaceutical company, developed the drug with its partner Plexxikon, a biotech company. It is being launched with a diagnostic test to screen patients for the BRAF mutation.

Professor Caroline Springer, the head of the gene targeting team at the Institute of Cancer Research in London, which is developing its own BRAF inhibitor, said the gene mutation was an "excellent target" for drug development: "If melanoma is caught in the early stages it is treatable. Once it has metastasised [spread to other organs] there is nothing. Survival is very low.

"Our agent is very different from [PLX4032]. We intend to trial it at the Royal Marsden Hospital in London. We are optimistic there will be a trial.

"I think Roche are in the lead – they are certainly getting there quite quickly but there is a long way to go. It is obviously very exciting to have a drug whose potential could be very good."

Half a dozen BRAF inhibitors were being prepared for clinical trials but the teams developing them were yet to prove they were safe and effective, Professor Springer said.

Cancer drugs: Why the future is uncertain

Q What is the future for cancer drugs?

A In the past, drugs have been developed to target a specific cancer – breast or lung or bowel – at a certain stage, early or advanced. Now drugs are being developed to target cancers with a specific genetic make-up.

Q What does this mean?

A It means the end of blockbuster drugs that treat everybody and the start of treatment tailored to groups of individuals. An early example is women with Her2-positive breast cancer (a specific genetic type which is more aggressive) who account for a third of all breast cancer cases, and can be treated successfully with Herceptin. For the two-thirds of women with Her2-negative breast cancer, the drug is useless.

Q What are the benefits of this approach?

A Patients avoid the risks – and the side effects – of being treated with drugs that don't work. An important part of cancer treatment is to reduce unnecessary suffering. At the same time it saves the NHS cash because drugs are not wasted on patients who won't benefit. Many cancer drugs cost thousands of pounds per patient.

Q Are there any downsides?

A Yes. If the potential market for a drug is reduced because it is targeted at a narrower patient group, then its price is likely to rise. So a cancer that costs £10,000 a year per patient to treat today could cost £20,000 to £40,000 to treat in the future.The cost will depend on the number of new drugs, the size of each patient group and hence the size of the market for each drug.

Q What is the future for drug research?

A Uncertain – because the more the market is segmented, the greater the uncertainty drug firms will face in recovering their investment from developing new drugs. Cancers with common genetic types that affect a large number of patients – such as BRAF-positive melanoma which accounts for 60 per cent of all melanoma cases – will be more likely to get new treatments.

people Emma Watson addresses celebrity nude photo leak
Katie Hopkins appearing on 'This Morning' after she purposefully put on 4 stone.
peopleKatie Hopkins breaks down in tears over weight gain challenge
Boris Johnson may be manoeuvring to succeed David Cameron
His band Survivor was due to resume touring this month
Life and Style
ebooksA superb mix of recipes serving up the freshest of local produce in a delicious range of styles
Life and Style
ebooksFrom the lifespan of a slug to the distance to the Sun: answers to 500 questions from readers
people'It can last and it's terrifying'
In this photo illustration a school student eats a hamburger as part of his lunch which was brought from a fast food shop near his school, on October 5, 2005 in London, England. The British government has announced plans to remove junk food from school lunches. From September 2006, food that is high in fat, sugar or salt will be banned from meals and removed from vending machines in schools across England. The move comes in response to a campaign by celebrity TV chef Jamie Oliver to improve school meals.
Arts and Entertainment
Life and Style
fashionModel of the moment shoots for first time with catwalk veteran
Life and Style
fashionPart of 'best-selling' Demeter scent range
Tom Cleverley
footballLoan move comes 17 hours after close of transfer window
Alexis Sanchez, Radamel Falcao, Diego Costa and Mario Balotelli
footballRadamel Falcao and Diego Costa head record £835m influx
Life and Style
fashionAngelina Jolie's wedding dressed revealed
Latest stories from i100
Have you tried new the Independent Digital Edition apps?

ES Rentals

    Independent Dating

    By clicking 'Search' you
    are agreeing to our
    Terms of Use.

    iJobs Job Widget
    iJobs General

    ICT Teacher

    £120 - £130 per day: Randstad Education Group: We are looking for an outstandi...

    Art & Design Teacher

    £120 - £130 per day: Randstad Education Group: We are looking for an outstandi...

    Assistant Management Accountant -S/West London - £30k - £35k

    £30000 - £35000 per annum: Ashdown Group: We are working with an exciting orga...

    Deputy Education Manager

    Negotiable: Randstad Education Sheffield: Deputy Education Manager required, S...

    Day In a Page

    'I’ll tell you what I would not serve - lamb and potatoes': US ambassador hits out at stodgy British food served at diplomatic dinners

    'I’ll tell you what I would not serve - lamb and potatoes'

    US ambassador hits out at stodgy British food
    Radio Times female powerlist: A 'revolution' in TV gender roles

    A 'revolution' in TV gender roles

    Inside the Radio Times female powerlist
    Endgame: James Frey's literary treasure hunt

    James Frey's literary treasure hunt

    Riddling trilogy could net you $3m
    Fitbit: Because the tingle feels so good

    Fitbit: Because the tingle feels so good

    What David Sedaris learnt about the world from his fitness tracker
    Saudis risk new Muslim division with proposal to move Mohamed’s tomb

    Saudis risk new Muslim division with proposal to move Mohamed’s tomb

    Second-holiest site in Islam attracts millions of pilgrims each year
    Alexander Fury: The designer names to look for at fashion week this season

    The big names to look for this fashion week

    This week, designers begin to show their spring 2015 collections in New York
    Will Self: 'I like Orwell's writing as much as the next talented mediocrity'

    'I like Orwell's writing as much as the next talented mediocrity'

    Will Self takes aim at Orwell's rules for writing plain English
    Meet Afghanistan's middle-class paint-ballers

    Meet Afghanistan's middle-class paint-ballers

    Toy guns proving a popular diversion in a country flooded with the real thing
    Al Pacino wows Venice

    Al Pacino wows Venice

    Ham among the brilliance as actor premieres two films at festival
    Neil Lawson Baker interview: ‘I’ve gained so much from art. It’s only right to give something back’.

    Neil Lawson Baker interview

    ‘I’ve gained so much from art. It’s only right to give something back’.
    The other Mugabe who is lining up for the Zimbabwean presidency

    The other Mugabe who is lining up for the Zimbabwean presidency

    Wife of President Robert Mugabe appears to have her sights set on succeeding her husband
    The model of a gadget launch: Cultivate an atmosphere of mystery and excitement to sell stuff people didn't realise they needed

    The model for a gadget launch

    Cultivate an atmosphere of mystery and excitement to sell stuff people didn't realise they needed
    Alice Roberts: She's done pretty well, for a boffin without a beard

    She's done pretty well, for a boffin without a beard

    Alice Roberts talks about her new book on evolution - and why her early TV work drew flak from (mostly male) colleagues
    Get well soon, Joan Rivers - an inspiration, whether she likes it or not

    Get well soon, Joan Rivers

    She is awful. But she's also wonderful, not in spite of but because of the fact she's forever saying appalling things, argues Ellen E Jones
    Doctor Who Into the Dalek review: A classic sci-fi adventure with all the spectacle of a blockbuster

    A fresh take on an old foe

    Doctor Who Into the Dalek more than compensated for last week's nonsensical offering